Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
US-England World Cup game seen by 19.98M on US television
Bird flu prompts slaughter of 1.8M chickens in Nebraska
NASDAQ:RVNC

Revance Therapeutics - RVNC Price Target & Analyst Ratings

$23.01
+0.22 (+0.97%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$22.32
$23.12
50-Day Range
$20.30
$30.66
52-Week Range
$11.27
$30.95
Volume
294,389 shs
Average Volume
1.27 million shs
Market Capitalization
$1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.90

Revance Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$37.90
64.71% Upside
High Prediction$65.00
Average Prediction$37.90
Low Prediction$24.00
TypeCurrent
11/27/21 to 11/27/22
1 Month Ago
10/28/21 to 10/28/22
3 Months Ago
8/29/21 to 8/29/22
1 Year Ago
11/27/20 to 11/27/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.90$37.80$27.83$25.20
Predicted Upside64.71% Upside52.39% Upside39.92% Upside30.75% Upside
Get Revance Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.


RVNC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RVNC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Revance Therapeutics Stock vs. The Competition

TypeRevance TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside64.71% Upside760.51% Upside12.75% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
377
66.02%
Underperform Votes
194
33.98%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.19%
Avg. Underperform Votes
398
31.81%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/16/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$35.00 ➝ $37.00+55.72%
11/15/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$36.00+51.52%
11/9/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$27.00 ➝ $25.00+16.88%
9/22/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00+27.91%
9/9/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$26.00 ➝ $30.00+18.58%
9/9/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$25.00 ➝ $29.00+14.62%
9/8/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$25.00 ➝ $35.00+42.86%
9/8/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$55.00 ➝ $65.00+170.38%
8/25/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$17.00 ➝ $24.00+12.89%
4/16/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$35.00 ➝ $31.00+109.32%
3/27/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
2/25/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$37.00 ➝ $40.00+48.81%
(Data available from 11/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RVNC Price Target - Frequently Asked Questions

What is Revance Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Revance Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 5 buy ratings for RVNC. The average twelve-month price prediction for Revance Therapeutics is $37.90 with a high price target of $65.00 and a low price target of $24.00. Learn more on RVNC's analyst rating history.

Do Wall Street analysts like Revance Therapeutics more than its competitors?

Analysts like Revance Therapeutics more than other Medical companies. The consensus rating for Revance Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how RVNC compares to other companies.

Do MarketBeat users like Revance Therapeutics more than its competitors?

MarketBeat users like Revance Therapeutics less than other Medical companies. 66.02% of MarketBeat users gave Revance Therapeutics an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Does Revance Therapeutics's stock price have much upside?

According to analysts, Revance Therapeutics's stock has a predicted upside of 58.99% based on their 12-month price targets.

What analysts cover Revance Therapeutics?

Revance Therapeutics has been rated by Barclays, Cowen, Cowen, Guggenheim, HC Wainwright, Mizuho, Morgan Stanley, Needham & Company LLC, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:RVNC) was last updated on 11/27/2022 by MarketBeat.com Staff